Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;17(4):421-429.
doi: 10.1159/000524789. Epub 2022 May 2.

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022

Marc Thill  1 , Diana Lüftner  2 , Cornelia Kolberg-Liedtke  3 , Ute-Susann Albert  4 , Maggie Banys-Paluchowski  5 , Ingo Bauerfeind  6 , Jens-Uwe Blohmer  7 , Wilfried Budach  8 , Peter Dall  9 , Eva Maria Fallenberg  10 , Peter A Fasching  11 , Tanja Fehm  12 , Michael Friedrich  13 , Bernd Gerber  14 , Oleg Gluz  15 , Nadia Harbeck  16 , Jörg Heil  17 , Jens Huober  18 , Christian Jackisch  19 , Hans-Heinrich Kreipe  20 , David Krug  21 , Thorsten Kühn  22 , Sherko Kümmel  23 , Sibylle Loibl  24 , Michael Lux  25 , Nicolai Maass  26   27 , Christoph Mundhenke  28 , Ulrike Nitz  15 , Tjoung-Won Park-Simon  29 , Toralf Reimer  14 , Kerstin Rhiem  30 , Achim Rody  5 , Marcus Schmidt  31 , Andreas Schneeweiss  32 , Florian Schütz  33 , Hans-Peter Sinn  34 , Christine Solbach  35 , Erich-Franz Solomayer  36 , Elmar Stickeler  37 , Christoph Thomssen  38 , Michael Untch  39 , Isabell Witzel  40 , Achim Wöckel  4 , Volkmar Müller  40 , Wolfgang Janni  41 , Nina Ditsch  42
Affiliations
Review

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022

Marc Thill et al. Breast Care (Basel). 2022 Aug.

Abstract

The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2022 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer.

Keywords: Arbeitsgemeinschaft Gynäkologische Onkologie; Diagnosis; Metastatic breast cancer; Recommendations; Treatment.

PubMed Disclaimer

Conflict of interest statement

Prof. Dr. Med. Marc Thill. Advisory boards: Agendia, Amgen, AstraZeneca, Aurikamed, Becton and Dickinson, ClearCut, Clovis, Daiichi Sankyo, Eisai, Exact Sciences, Gilead Science, Grünenthal, GSK, Lilly, MSD, Neodynamics, Novartis, Onkowissen, Organon, Pfizer, pfm Medical, Pierre-Fabre, Roche, Seagen, Sirius Pintuition, Sysmex. Manuscript support: Amgen, Clearcut, Clovis, pfm medical, Roche, Servier. Travel reimbursement: Amgen, art tempi, AstraZeneca, Clovis, Connect Medica, Daiichi Sankyo, Eisai, Exact Sciences, Lilly, MSD, Novartis, Pfizer, pfm Medical, Roche, Seagen. Congress support: Amgen, AstraZeneca, Daiichi Sanyko, Novartis, Pfizer, Roche. Lecture: Amgen, art tempi, AstraZeneca, Clovis, Connect Medica, Daiichi Sankyo, Exact Sciences, Gilead Science, Hexal, I-Med-Institute, Jörg Eickeler, Lilly, MSD, Novartis, Onkowissen, Pfizer, pfm medical, Roche, Seagen, Sysmex, Vifor, Viatris. Trial funding: Endomagnetics, Exact Sciences. Prof. Dr. Med. Diana Lüftner. Advisory board: AstraZeneca, Eli Lilly, GSK, Novartis, Onkowissen, High5MD, Loreal, Pfizer, Roche, TEVA, Gilead Science. Lecture: AstraZeneca, Eli Lilly, GSK, Novartis, Onkowissen, High5MD, Loreal, Pfizer, Roche, TEVA, Gilead Science. Prof. Dr. Med. Cornelia Kolberg-Liedtke. Advisory board: Aurikamed, Novartis, Pfizer, MSD, Novartis, Gilead Science, Seagen, Lilly, Agendia, Daiichi Sankyo. Lecture: Roche, Novartis, Pfizer, Exact Sciences, Amgen, AstraZeneca, Carl Zeiss Meditec, NCO Hannover. Other: Gilead Science, POMME. Stockholding: Phaon Scientific. Trial Funding: Gilead Science. Prof. Dr. Med. Ute-Susann Albert. Lectures and/or consulting: Pfizer, Novartis, Aurikamed. PD Dr. Malgorzata Banys-Paluchowski. Advisory board: Novartis, Roche, LIlly, Pfizer, GSK, MSD. Lecture: Novartis, Pfizer, pfm medical, Seagen, Daiichi Sankyo, Lilly, Roche, Amgen. Trial funding: Mammotome, Exact Sciences, Merit Medical, Endomag. Dr. Med. Ingo Bauerfeind. No conflicts of interest. Prof. Dr. Med. Jens-Uwe Blohmer. Honoraria: Astrazeneca, Eisai, Lilly, MSD, Novartis, Pfizer, Roche, Seagen. Prof. Dr. Med. Wilfried Budach. Lecture: Merck, medpublico GmbH, BVDST. Prof. Dr. Med. Peter Dall. Advisory Boards: Gilead Science, Roche. Lecture: Novartis, AstraZeneca, Pfizer. PD Dr. Med. Eva Maria Fallenberg. No conflicts of interest. Prof. Dr. Med. Peter A. Fasching. Advisory board: Pfizer, Novartis, Roche, Daiichi Sankyo, Eisai, AstraZeneca, Lilly, MSD, Seagen, Agendia, Pierre Fabre, Sanofi Aventis, Gilead Science. Lecture: Pfizer, Novartis, Roche, Daiichi Sankyo, Eisai, AstraZeneca, Lilly, MSD, Seagen, Gilead Science. Other: Onkowissen, art tempi. Prof. Dr. Med. Tanja N. Fehm. Onkowissen. Prof. Dr. Med. Michael Friedrich. Advisory Board: Gilead Science. Other honoraria: Roche, MSD. Stockholding: Biontech, Curevac. Prof. Dr. Med. Bernd Gerber. Lecture honoraria: Roche, AstraZeneca, Seagen, Novartis, Pfizer, MedConcept. Others: Pfizer. PD Dr. Med. Oleg Gluz. No conflicts of interest. Prof. Dr. Med. Nadia Harbeck. Honoraria for lectures and/or consulting: Amgen, AstraZeneca, Daiichi Sanyko, Gilead Science, Lilly, MSD, Novartis, Pierre-Fabre, Pfizer, Roche, Sandoz, Seagen, Exact Sciences. Minority shareholder: Westdeutsche Studiengruppe (WSG). Prof. Dr. Med. Jörg Heil. Advisory board: Polytech. Trial funding: pfm medical. Prof. Dr. Med. Jens Huober. Lecture: Gilead Science, Seagen, Lilly, Novartis, Daiichi Sankyo, GSK, Pfizer. Prof. Dr. Med. Christian Jackisch. Advisory board: Exact Sciences, Pfizer, Roche, GSK, Pierre-Fabre. Lecture: AstraZeneca, Lilly, Novartis. Prof. Dr. Med. Hans-Heinrich Kreipe. Advisory board: Lilly. Lecture: AstraZeneca, Roche, Daiichi Sankyo, Pfizer. Dr. David Krug. Lecture: MSD, ESO, ESMO, medupdate GmbH. Trial funding: Merck. Prof. Dr.med. Thorsten Kühn. Advisory Board: Sysmex, Neodynamics. Trial funding: Merit Medical, Endomag, Mammotome. Lecture: Pfizer. Prof. Dr. Med. Sherko Kümmel. Lecture: Roche, Lilly, Exact Sciences, Novartis, Amgen, Daiichi Sankyo, AstraZeneca, Somatex, MSD, Pfizer, pfm medical, Seagen, Gilead Science, Agendia. Other honoraria: Roche, Daiichi Sankyo, Sonoscape Advisory board: Lilly, MSD, Roche. Prof. Dr. Med. Sibylle Loibl. Trial funding: Abbvie, AstraZeneca, Celgene, Daiichi Sankyo, Gilead Science, Novartis, Pfizer, Roche. Lecture: Abbvie, Amgen, AstraZeneca, Bayer, BMS, Celgene, Daiichi Sankyo, Eirgenix, GSK, Gilead Science, Lilly, Merck, Novartis, Pfizer, Pierre Fabre, Prime/Medscape, Puma, Roche, Samsung. Prof. Dr. Med. Michael Patrick Lux. Lecture: Lilly, Roche, MSD, Onkowissen, Novartis, Pfizer, Exact Sciences, Daiichi Sankyo, Gilead, Grünenthal, Eisai, AstraZeneca. Advisory board: pfm medical, Saman Tree, Sysmex, Lilly, AstraZeneca, MSD, Novartis, Pfizer, Eisai, Gilead, Exact Sciences, Daiichi Sankyo, Grünenthal, Pierre Fabre, PharmaMar, Roche. Other: Medac, Pfizer. Prof. Dr. Med. Nicolai Maass. Advisory board: Amgen, Grünenthal. Lecture: AstraZeneca, Pierre Fabre, Clovis, Seagen, Lilly, MSD, Novartis, Pfizer. Prof. Dr. Med. Christoph Mundhenke. Not specified. Prof. Dr. Med. Ulrike Nitz. Not specified. Prof. Dr. Tjoung-Won Park-Simon. Advisory board: Roche, AstraZeneca, GSK, Pfizer, Lilly, MSD, Exact Sciences, Daiichi Sankyo, Seagen, Novartis, Gilead Science. Lecture: Roche, AstraZeneca, GSK, Pfizer, Lilly, MSD, NCO, Exact Sciences, Daiichi Sankyo, Seagen, Novartis, Gilead Science. Prof. Dr. Med. Toralf Reimer. Trial funding: Novartis, German Cancer Aid and Else Kroener-Fresenius-Stiftung. Advisory board: MSD, Novartis, Myriad. Lecture: Pfizer, Novartis, Roche, AstraZeneca. PD. Dr. Med. Kerstin Rhiem. Lecture: AstraZeneca, Amgen, MDS, Medupdate, Medconcept. Prof. Dr. Med. Achim Rody. Advisory board: AstraZeneca, Novartis, Roche, Exact Sciences, Pierre Fabre, Lilly, Seagen, Amgen, MSD. Lecture: Pfizer, Celgene, Eisai. Trial funding: Eisai. Prof. Dr. Med. Marcus Schmidt. Advisory board: AstraZeneca, Novartis, Eisai, Lilly, MSD, Pierre Fabre, Pfizer, Roche, Seagen. Prof. Dr. Med. Andreas Schneeweiss. Lecture: Amgen, AstraZeneca, Aurikamed, Clinsol, ConnectMedica, Gilead Science, GSK, I-Med, Lilly, MSD, Nanostring, Novartis, Onkowissen, Promedicis, Pfizer, Pierre Fabre, Roche, Seagen, StreamedUp. Other: Thieme. Prof. Dr. Med. Florian Schütz. Lecture: Amgen, AstraZeneca, Eisai, Pfizer, Novartis, Onkowissen. Advisory board: Amgen, Lilly, MSD, Eisai. Prof. Dr. Med. Hans-Peter Sinn. Advisory board: Diaceutics. Prof. Dr. Med. Christine Solbach. Lecture: DiaLog Service GmbH, Jörg Eickeler, Pfizer, MedConcept, Medicultus, GBG, Dt. Röntgengesellschaft, BVF Akademie, LÄK Hessen Akademie, Meet the Expert Academy. Advisory board: MSD, Roche. Prof. Dr. Med. Erich-Franz Solomayer. Lecture: Universitätsklinikum Freiburg, MedConcept, Saarländische Krebsgesellschaft, Bsh medical Communications GmbH, Pfizer, AstraZeneca. Other: Roche, Amgen, Clovis, AstraZeneca, Novartis, GSK, MSD, Eisai, Pfizer, Medac, Pierre Fabre, PharmaMar, Daiichi Sankyo, Samsung, Primus, matramed, GE Healthcare. Trial funding: Medac, GBG, AMS, AstraZeneca, Pfizer, Novartis, AGO Research GmbH, WSG, Universitätsklinikum Tübingen, Roche. Prof. Dr. Med. Elmar Stickeler. Advisory boards: Gilead, Iomedico, Lilly, MSD, Seagen. Lecture: Pfizer, Bsh Düsseldorf, Gilead, Iomedico, PharmaMar, Onkowissen, Roche. Prof. Dr. Med. Christoph Thomssen. Advisory board: Amgen, AstraZeneca, Hexal, Lilly, MSD, Pfizer, Roche, Seagen. Lecture: Klnikum Wolfsburg, Medicultus, Medupdate, Novartis, Pfizer, Roche, AstraZeneca, Daiichi Sankyo, Jörg Eickeler, Evang. KH Wittenberg, Gilead Science. Other: Aurikamed, ForumSanitas/Merit Corporate, Onkowissen, Pfizer, Daiichi Sankyo. Prof. Dr. Med. Michael Untch. Advisory board: Lilly, AstraZeneca, Pfizer, Roche, Pierre Fabre, Sanofi Aventis, Gilead Science. Lecture: Daiichi Sankyo, Lilly, Seagen, Novartis, AstraZeneca, Roche, Eisai, MSD, I-Med_Insitute, Onkowissen, art tempi, High5Med. Prof. Dr. Isabell Witzel. Lecture: Daiichi Sankyo, Pfizer, MSD, Lilly, Seagen, AstraZeneca. Other: Onkowissen Prof. Dr. Med. Achim Wöckel. Advisory board: Amgen, AstraZeneca, Aurikamed, Celgene, Eisai, Lilly, Novartis, Pfizer, Roche, Tesaro, Sirtex, MSD, Genomic Health, Pierre Fabre, Clovis, Organon. Prof. Dr. Med. Volkmar Müller. Lecture: Amgen, AstraZeneca, Daiichi Sankyo, eisai, GSK, Pfizer, MSD, Medac, Novartis, Roche, Teva, Seagen, Onkowissen, High5Oncology, Medscape, Gilead. Advisory board: Hexal, Roche, Pierre Fabre, Amgen, Clinsol, Novartis, MSD, Daiichi Sankyo, Eisai, Lilly, Sanofi Aventis, Seagen, Gilead Science. Trial funding: Novartis, Roche, Seagen, Genetech. Other: Daiichi Sankyo. Prof. Dr. Med. Wolfgang Janni. Lecture: Amgen, AstraZeneca, Daiichi Sankyo, Lilly, MSD, Novartis, Pfizer, Roche, Seagen, Gilead Science. Trial Funding: Amgen, AstraZeneca, Lilly, Novartis, Roche. Prof. Dr. Med. Nina Ditsch. Not specified.

Figures

Fig. 1
Fig. 1
Treatment algorithm for metastatic HER2+ BC.
See this image and copyright information in PMC

Similar articles

  • Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024.
    Thill M, Janni W, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Ditsch N, Fallenberg EM, Fasching PA, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf A, Heil J, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Mundhenke C, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Würstlein R, Müller V, Park-Simon TW. Thill M, et al. Breast Care (Basel). 2024 Jun;19(3):183-191. doi: 10.1159/000538753. Epub 2024 Apr 10. Breast Care (Basel). 2024. PMID: 38894953 Free PMC article. Review.
  • AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023.
    Thill M, Kolberg-Liedtke C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, Budach W, Dall P, Ditsch N, Fallenberg EM, Fasching PA, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf AD, Heil J, Huober J, Jackisch C, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Mundhenke C, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Würstlein R, Janni W, Park-Simon TW. Thill M, et al. Breast Care (Basel). 2023 Aug;18(4):306-315. doi: 10.1159/000531579. Epub 2023 Jun 16. Breast Care (Basel). 2023. PMID: 37900553 Free PMC article. Review.
  • AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2025.
    Thill M, Janni W, Albert US, Banys-Paluchowski M, Bartsch R, Bauerfeind I, Bjelic-Radisic V, Blohmer J, Budach W, Dall P, Ditsch N, Fallenberg EM, Fasching PA, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf A, Heil J, Hörner-Rieber J, Huober J, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Mundhenke C, Reinisch M, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, van Mackelenbergh M, Witzel I, Wöckel A, Würstlein R, Müller V, Park-Simon TW. Thill M, et al. Breast Care (Basel). 2025 Mar 8:1-12. doi: 10.1159/000545018. Online ahead of print. Breast Care (Basel). 2025. PMID: 40331128 Free PMC article. Review.
  • AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019.
    Thill M, Jackisch C, Janni W, Müller V, Albert US, Bauerfeind I, Blohmer J, Budach W, Dall P, Diel I, Fasching PA, Fehm T, Friedrich M, Gerber B, Hanf V, Harbeck N, Huober J, Kolberg-Liedtke C, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Möbus V, Müller-Schimpfle M, Mundhenke C, Nitz U, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Wenz F, Witzel I, Wöckel A, Ditsch N. Thill M, et al. Breast Care (Basel). 2019 Aug;14(4):247-255. doi: 10.1159/000500999. Epub 2019 Jul 30. Breast Care (Basel). 2019. PMID: 31558898 Free PMC article. Review.
  • Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024.
    Park-Simon TW, Müller V, Albert US, Banys Paluchowski M, Bauerfeind I, Blohmer JU, Budach W, Dall P, Ditsch N, Fallenberg EM, Fasching PA, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf AD, Heil J, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Mundhenke C, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Wuerstlein R, Wöckel A, Janni W, Thill M. Park-Simon TW, et al. Breast Care (Basel). 2024 Jun;19(3):165-182. doi: 10.1159/000538596. Epub 2024 Apr 18. Breast Care (Basel). 2024. PMID: 38894952 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Empfehlungen Gynäkologische Onkologie Kommission Mamma 2022. Available from: www.ago-online.
    1. André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019 May;380:1929–40. - PubMed
    1. Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2016 Sep;34:2961–8. - PubMed
    1. Hymann DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Feb;554:189–94. - PMC - PubMed
    1. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018 Dec;15:731–47. - PMC - PubMed